Trump Has Won On Drug Prices – According To Breitbart
Executive Summary
The pharmaceutical industry is always struggling to get good press when it comes to drug prices. But a recent headline in Breitbart News is one to savor – as long as the President believes it.
You may also be interested in...
Marathon's Bad News May Help Industry In Pricing Debate
Wall Street Journal brings Marathon Pharmaceuticals back to the front pages – but this time to report that the company is expected to shut down after a 'drug-price revolt.' The rest of the industry should hope the headline catches the President’s eye.
PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.